Related Experiment Videos
Genetic editing of dysfunctional myocardium
Roger J Hajjar1, Fawzia Huq, Takashi Matsui
1Massachusetts General Hospital, Boston, MA, USA.
The Medical Clinics of North America
|April 16, 2003
Summary
Gene therapy shows promise for heart failure (HF) by enhancing calcium transport and cardiomyocyte survival. Further research in large animal models is needed to ensure safety and efficacy for clinical application.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gene Therapy
Background:
- Advances in vector technology and understanding of heart failure (HF) pathogenesis support gene therapy considerations.
- Strategies enhancing sarcoplasmic calcium transport and cardiomyocyte survival signaling show promise in HF models.
Purpose of the Study:
- To explore the potential of gene therapy for treating heart failure (HF).
- To validate molecular targets for therapeutic intervention through gene transfer studies.
- To assess the contribution of specific pathways to cardiac dysfunction.
Main Methods:
- Utilizing gene transfer to study cardiomyocyte function and survival pathways.
- Investigating strategies to enhance sarcoplasmic calcium transport.
- Developing and testing clinical grade vectors and delivery systems.
Main Results:
- Substantial evidence supports enhancing sarcoplasmic calcium transport in HF models.
- Modulating antiapoptotic signaling appears promising for cardiomyocyte survival and function.
- Gene transfer aids in understanding pathway contributions to cardiac dysfunction.
Conclusions:
- Gene therapy holds potential for heart failure treatment, with promising targets identified.
- Further development and validation in large animal models are crucial for clinical translation.
- Progress in vector technology and HF pathogenesis offers cautious optimism for future therapies.